MATTHEW COLEMAN: Open Payments
NPI 1972685683 · HAUGHTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 22 payments from 10 companies in 2025. Trend: 2023 $130 · 2024 $294 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $195 |
| Novo Nordisk Inc | 3 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $43 |
| PFIZER INC. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| ABBVIE INC. | 1 | $14 |
| Corium, LLC | 1 | $13 |
Products named: AIRSUPRA, XIFAXAN, NURTEC ODT, MOUNJARO, Wegovy, BREZTRI, Auvelity, Ozempic.
Industry payments across LA — which companies pay providers there.
